NCT01302119
Completed
Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults
ConditionsOnychomycosis of Toenails
Overview
- Phase
- Phase 3
- Intervention
- AN2690 Topical Solution, 5%
- Conditions
- Onychomycosis of Toenails
- Sponsor
- Pfizer
- Enrollment
- 604
- Locations
- 1
- Primary Endpoint
- Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of distal subungual onychomycosis affecting at least one great toenail
- •KOH positive at screening
- •Willingness not to use any other products including nail polish applied to the toenails during the study
- •Women of childbearing potential who are currently sexually active must agree to use contraception for the entire study period
Exclusion Criteria
- •Concurrent or recent use of certain topical or systemic medications without a sufficient washout period
- •History of any significant chronic fungal disease other than onychomycosis
- •Significant confounding conditions as assessed by study doctor
- •Participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study
- •Pregnancy or lactation
Arms & Interventions
AN2690 Topical Solution, 5%
AN2690 Topical Solution, 5%
Intervention: AN2690 Topical Solution, 5%
Solution Vehicle
Solution Vehicle
Intervention: Solution Vehicle
Outcomes
Primary Outcomes
Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52
Time Frame: Week 52
No clinical evidence of onychomycosis as evidenced by normal toenail plate, no onycholysis, and no subungual hyperkeratosis, and negative KOH wet mount and negative fungal culture.
Secondary Outcomes
- Completely Clear or Almost Clear Target Great Toenail at Week 52(Week 52)
- Treatment Success (Completely Clear or Almost Clear Nail and Negative Mycology) of Target Great Toenail at Week 52(Week 52)
- Negative Mycology of Target Great Toenail at Week 52(Week 52)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the ToenailOnychomycosis of ToenailsNCT01270971Pfizer594
Completed
Phase 2
A Six Week Topical Cream Study for Subjects With Ichthyosis VulgarisIchthyosis VulgarisNCT03173547Crown Laboratories, Inc.80
Completed
Phase 2
Study of Different Doses of a Novel Treatment for OnychomycosisDistal, Subungual OnychomycosisNCT00679965Pfizer159
Completed
Phase 2
Study of Different Doses of a Novel Treatment for OnychomycosisDistal, Subungual OnychomycosisNCT00679770Pfizer28
Completed
Phase 3
Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big ToenailOnychomycosisNCT00443820Novartis Pharmaceuticals526